Potential synergistic benefits in reducing inflammation and improving lung function could be achieved through combination therapies targeting multiple aspects of COPD, including but not limited to NETosis and cGAS/TLR9 pathways. The gene discussed is CGAS; the disease is chronic obstructive pulmonary disease.